Class information for:
Level 1: CRIZOTINIB//ANAPLASTIC LYMPHOMA KINASE//ALK

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
5267 1648 38.6 90%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
6 4 GASTROENTEROLOGY & HEPATOLOGY//ONCOLOGY//SURGERY 1371034
216 3       NON SMALL CELL LUNG CANCER//LUNG CANCER//THORAC SURG 51214
1717 2             GEFITINIB//EGFR MUTATION//MIDKINE 6648
5267 1                   CRIZOTINIB//ANAPLASTIC LYMPHOMA KINASE//ALK 1648

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 CRIZOTINIB authKW 3187462 15% 72% 239
2 ANAPLASTIC LYMPHOMA KINASE authKW 2078492 12% 58% 193
3 ALK authKW 2030993 15% 46% 239
4 EML4 ALK authKW 1112239 5% 73% 82
5 ALK INHIBITOR authKW 955454 3% 90% 57
6 ROS1 authKW 843148 4% 71% 64
7 ALECTINIB authKW 816729 3% 96% 46
8 CERITINIB authKW 699101 3% 88% 43
9 ANAPLASTIC LYMPHOMA KINASE ALK authKW 573636 3% 61% 51
10 ALK REARRANGEMENT authKW 538946 2% 73% 40

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 Oncology 23245 61% 0% 1002
2 Respiratory System 6483 17% 0% 275
3 Pathology 2175 11% 0% 178
4 Cell Biology 690 12% 0% 202
5 Chemistry, Medicinal 337 5% 0% 82
6 Hematology 225 4% 0% 72
7 Medical Laboratory Technology 171 2% 0% 32
8 Genetics & Heredity 158 6% 0% 91
9 Medicine, Research & Experimental 96 4% 0% 67
10 Pharmacology & Pharmacy 60 6% 0% 104

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 PATHOL PROJECT MOL TARGETS 139316 1% 40% 19
2 P DISTHORAC DIS 74104 0% 67% 6
3 NEW YORK CANC 51299 0% 46% 6
4 LOWE THORAC ONCOL 50911 1% 13% 22
5 PREDICT MOL MED 50010 1% 30% 9
6 WORLDWIDE DISCOVERY 43939 1% 22% 11
7 ENDOSCOP SECT PNEUMOL 41684 0% 75% 3
8 DIANAS TER EUT 40546 1% 24% 9
9 COURSE MED SCI CARDIOL P MED NEPHROL 37054 0% 100% 2
10 INSERM1151 37054 0% 100% 2

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 JOURNAL OF THORACIC ONCOLOGY 129978 8% 5% 137
2 LUNG CANCER 37721 6% 2% 95
3 CLINICAL LUNG CANCER 14014 1% 3% 24
4 THORACIC CANCER 5177 1% 2% 12
5 ONCOTARGET 4661 3% 0% 56
6 CLINICAL CANCER RESEARCH 4122 4% 0% 58
7 CANCER DISCOVERY 3245 1% 2% 9
8 EXPERT REVIEW OF ANTICANCER THERAPY 2514 1% 1% 15
9 THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY 2051 0% 3% 4
10 ONCOLOGY RESEARCH AND TREATMENT 1850 0% 2% 5

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 CRIZOTINIB 3187462 15% 72% 239 Search CRIZOTINIB Search CRIZOTINIB
2 ANAPLASTIC LYMPHOMA KINASE 2078492 12% 58% 193 Search ANAPLASTIC+LYMPHOMA+KINASE Search ANAPLASTIC+LYMPHOMA+KINASE
3 ALK 2030993 15% 46% 239 Search ALK Search ALK
4 EML4 ALK 1112239 5% 73% 82 Search EML4+ALK Search EML4+ALK
5 ALK INHIBITOR 955454 3% 90% 57 Search ALK+INHIBITOR Search ALK+INHIBITOR
6 ROS1 843148 4% 71% 64 Search ROS1 Search ROS1
7 ALECTINIB 816729 3% 96% 46 Search ALECTINIB Search ALECTINIB
8 CERITINIB 699101 3% 88% 43 Search CERITINIB Search CERITINIB
9 ANAPLASTIC LYMPHOMA KINASE ALK 573636 3% 61% 51 Search ANAPLASTIC+LYMPHOMA+KINASE+ALK Search ANAPLASTIC+LYMPHOMA+KINASE+ALK
10 ALK REARRANGEMENT 538946 2% 73% 40 Search ALK+REARRANGEMENT Search ALK+REARRANGEMENT

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 HALLBERG, B , PALMER, RH , (2016) THE ROLE OF THE ALK RECEPTOR IN CANCER BIOLOGY.ANNALS OF ONCOLOGY. VOL. 27. ISSUE . P. 4 -15 111 82% 4
2 HALLBERG, B , PALMER, RH , (2013) MECHANISTIC INSIGHT INTO ALK RECEPTOR TYROSINE KINASE IN HUMAN CANCER BIOLOGY.NATURE REVIEWS CANCER. VOL. 13. ISSUE 10. P. 685-700 125 61% 106
3 OU, SHI , BARTLETT, CH , MINO-KENUDSON, M , CUI, J , IAFRATE, AJ , (2012) CRIZOTINIB FOR THE TREATMENT OF ALK-REARRANGED NON-SMALL CELL LUNG CANCER: A SUCCESS STORY TO USHER IN THE SECOND DECADE OF MOLECULAR TARGETED THERAPY IN ONCOLOGY.ONCOLOGIST. VOL. 17. ISSUE 11. P. 1351 -1375 102 72% 82
4 SOLOMON, B , WILNER, KD , SHAW, AT , (2014) CURRENT STATUS OF TARGETED THERAPY FOR ANAPLASTIC LYMPHOMA KINASE-REARRANGED NON-SMALL CELL LUNG CANCER.CLINICAL PHARMACOLOGY & THERAPEUTICS. VOL. 95. ISSUE 1. P. 15 -23 70 89% 33
5 PALMIROTTA, R , QUARESMINI, D , LOVERO, D , SILVESTRIS, F , (2017) ALK GENE ALTERATIONS IN CANCER: BIOLOGICAL ASPECTS AND THERAPEUTIC IMPLICATIONS.PHARMACOGENOMICS. VOL. 18. ISSUE 3. P. 277 -292 84 86% 0
6 LIAO, BC , LIN, CC , SHIH, JY , YANG, JCH , (2015) TREATING PATIENTS WITH ALK-POSITIVE NON-SMALL CELL LUNG CANCER: LATEST EVIDENCE AND MANAGEMENT STRATEGY.THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. VOL. 7. ISSUE 5. P. 274 -290 75 79% 6
7 PALMER, RH , VERNERSSON, E , GRABBE, C , HALLBERG, B , (2009) ANAPLASTIC LYMPHOMA KINASE: SIGNALLING IN DEVELOPMENT AND DISEASE.BIOCHEMICAL JOURNAL. VOL. 420. ISSUE . P. 345-361 110 48% 177
8 MARINO-ENRIQUEZ, A , DAL CIN, P , (2013) ALK AS A PARADIGM OF ONCOGENIC PROMISCUITY: DIFFERENT MECHANISMS OF ACTIVATION AND DIFFERENT FUSION PARTNERS DRIVE TUMORS OF DIFFERENT LINEAGES.CANCER GENETICS. VOL. 206. ISSUE 11. P. 357-373 101 59% 16
9 YE, MX , ZHANG, XX , LI, N , ZHANG, Y , JING, PY , CHANG, N , WU, JX , REN, XL , ZHANG, J , (2016) ALK AND ROS1 AS TARGETED THERAPY PARADIGMS AND CLINICAL IMPLICATIONS TO OVERCOME CRIZOTINIB RESISTANCE.ONCOTARGET. VOL. 7. ISSUE 11. P. 12289 -12304 65 72% 4
10 IRAGAVARAPU, C , MUSTAFA, M , AKINLEYE, A , FURQAN, M , MITTAL, V , CANG, SD , LIU, DL , (2015) NOVEL ALK INHIBITORS IN CLINICAL USE AND DEVELOPMENT.JOURNAL OF HEMATOLOGY & ONCOLOGY. VOL. 8. ISSUE . P. - 64 71% 22

Classes with closest relation at Level 1


Rank Class id link
1 147 GEFITINIB//EGFR MUTATION//ERLOTINIB
2 7850 ANAPLASTIC LARGE CELL LYMPHOMA//LYMPHOMATOID PAPULOSIS//CD30
3 15038 TTF 1//NAPSIN A//THYROID TRANSCRIPTION FACTOR 1
4 13215 MIDKINE//PLEIOTROPHIN//HB GAM
5 5057 INFLAMMATORY PSEUDOTUMOR//INFLAMMATORY MYOFIBROBLASTIC TUMOR//PLASMA CELL GRANULOMA
6 19243 TRANS SPLICING//SPLICED LEADER//CHIMERIC RNA
7 28465 PLASMABLASTIC LYMPHOMA//PLASMABLASTIC//ORAL CAVITY LYMPHOMA
8 3965 EVOLUT CANC//CANCER GENOME//CANCER GENOMICS
9 3176 BRONCHIOLOALVEOLAR CARCINOMA//GROUND GLASS OPACITY//SEGMENTECTOMY
10 598 NEUROBLASTOMA//MYCN//MYCN AMPLIFICATION

Go to start page